Sanofi Sponsored ADR Aktie News

Sanofi (SNY) remains a Buy, driven by Dupixent's robust growth and expanding indications, notably with the recent COPD launch. SNY's Q3 saw total revenues rise 7% CER to €12.43 billion, with Dupixent contributing over €4 billion for the first time. Beyond Dupixent, SNY is diversifying with specialty launches like Altuviiio in hemophilia and Beyfortus in RSV, plus a strong pipeline and share buy...

Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript

Sanofi stock jumped early Friday on better-than-expected third-quarter sales and earnings, and a strong showing from Dupixent.

Pharmaceutical launches and increased demand for its blockbuster Dupixent drug lifted net sales by 7% in the third quarter.

France's Sanofi reported a third-quarter profit that beat analysts' expectations on Friday, boosted by strong demand for its anti-inflammatory drug Dupixent and newer medicines.

Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care

Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

Sanofi's Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program